Pyruvate will repair injured mitochondria to kill the tumor. Also we have discovered that pyruvate can “up-regulate” NO, which can kill viruses, infections, and tumors. The following press release from Harvard independently confirms that our lead patented compound, pyruvate, can shrink or kill tumors:
If there is one common problem that residents in the United States are consistently faced with, it is suffering from some form of asthma or an asthma-like illness. Currently, the Centers for Disease Control and Prevention (often recognized as the C.D.C.), has estimated that nearly 20.3 million people are suffering from a condition similar to the aforementioned. Additionally, nearly 33 million individuals have been diagnosed with a form of asthma during their lives.
July 21, 2004 - Emphycorp committed to performing five more clinical studies with their Phase II investigational new respiratory drug, N115. With this proprietary formula Emphycorp has introduced to the medical market a new formula that is revolutionary to the medical industry as a multi use product and formula. These clinicals were completed by 2010, with great results and reported to the FDA.
Up until the recent acclaim of EmphyCorp's proprietary technology, N115, the primary treatment for asthmatic bronchitis and chronic obstructive pulmonary diseases was the use of corticosteroids. Corticosteroids are typically involved in a very wide range of physiological processes such as the body's stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels and overall behavior.